Terms: = Ovarian cancer AND NT5C2, ENSG00000076685, 22978, P49902, PNT5, NT5B, GMP, cN-II AND Treatment
12 results:
1. The STING pathway: Therapeutic vulnerabilities in ovarian cancer.
Shakfa N; Li D; Nersesian S; Wilson-Sanchez J; Koti M
Br J Cancer; 2022 Sep; 127(4):603-611. PubMed ID: 35383278
[TBL] [Abstract] [Full Text] [Related]
2. Synthesis and antiproliferative activity of hindered, chiral 1,2-diaminodiamantane platinum(II) complexes.
Bakhonsky VV; Pashenko AA; Becker J; Hausmann H; De Groot HJM; Overkleeft HS; Fokin AA; Schreiner PR
Dalton Trans; 2020 Oct; 49(40):14009-14016. PubMed ID: 33078783
[TBL] [Abstract] [Full Text] [Related]
3. ovarian cancer Cells Commonly Exhibit Defective STING Signaling Which Affects Sensitivity to Viral Oncolysis.
de Queiroz NMGP; Xia T; Konno H; Barber GN
Mol Cancer Res; 2019 Apr; 17(4):974-986. PubMed ID: 30587523
[TBL] [Abstract] [Full Text] [Related]
4. Nanoscale Coordination Polymers Codeliver Carboplatin and Gemcitabine for Highly Effective treatment of Platinum-Resistant ovarian cancer.
Poon C; Duan X; Chan C; Han W; Lin W
Mol Pharm; 2016 Nov; 13(11):3665-3675. PubMed ID: 27712076
[TBL] [Abstract] [Full Text] [Related]
5. Photosensitive Pt(IV)-azide prodrug-loaded nanoparticles exhibit controlled drug release and enhanced efficacy in vivo.
Xiao H; Noble GT; Stefanick JF; Qi R; Kiziltepe T; Jing X; Bilgicer B
J Control Release; 2014 Jan; 173():11-7. PubMed ID: 24511610
[TBL] [Abstract] [Full Text] [Related]
6. Cyclic gmp/protein kinase G type-Iα (PKG-Iα) signaling pathway promotes CREB phosphorylation and maintains higher c-IAP1, livin, survivin, and Mcl-1 expression and the inhibition of PKG-Iα kinase activity synergizes with cisplatin in non-small cell lung cancer cells.
Wong JC; Bathina M; Fiscus RR
J Cell Biochem; 2012 Nov; 113(11):3587-98. PubMed ID: 22740515
[TBL] [Abstract] [Full Text] [Related]
7. Urinary cyclic gmp after treatment of gynecological cancer. A prognostic marker of clinical outcome.
Orbo A; Hanevik M; Jaeger R; Van Heusden S; Sager G
Anticancer Res; 2007; 27(4C):2591-6. PubMed ID: 17695420
[TBL] [Abstract] [Full Text] [Related]
8. In vivo tracking of macrophage activated killer cells to sites of metastatic ovarian carcinoma.
Ritchie D; Mileshkin L; Wall D; Bartholeyns J; Thompson M; Coverdale J; Lau E; Wong J; Eu P; Hicks RJ; Prince HM
Cancer Immunol Immunother; 2007 Feb; 56(2):155-63. PubMed ID: 16733671
[TBL] [Abstract] [Full Text] [Related]
9. Mechanisms associated with the expression of cisplatin resistance in a human ovarian tumor cell line following exposure to fractionated X-irradiation in vitro.
Dempke WC; Shellard SA; Hosking LK; Fichtinger-Schepman AM; Hill BT
Carcinogenesis; 1992 Jul; 13(7):1209-15. PubMed ID: 1638688
[TBL] [Abstract] [Full Text] [Related]
10. Tumour cell activity markers in epithelial ovarian cancer: are biochemical and cytometric indices complementary?
Redman CW; Finn C; Ward K; Kelly K; Buxton EJ; Varma R; Shortland-Webb W; Luesley DM
Br J Cancer; 1990 May; 61(5):755-8. PubMed ID: 2159769
[TBL] [Abstract] [Full Text] [Related]
11. Cyclic gmp in urine to monitor the response to ovarian cancer to therapy.
Turner GA; Ellis RD; Guthrie D; Latner AL; Ross WM; Skillen AW
Br J Obstet Gynaecol; 1982 Sep; 89(9):760-4. PubMed ID: 6288064
[TBL] [Abstract] [Full Text] [Related]
12. Urine cyclic nucleotide concentrations in cancer and other conditions; cyclic gmp: a potential marker for cancer treatment.
Turner GA; Ellis RD; Guthrie D; Latner AL; Monaghan JM; Ross WM; Skillen AW; Wilson RG
J Clin Pathol; 1982 Aug; 35(8):800-6. PubMed ID: 6286732
[TBL] [Abstract] [Full Text] [Related]
